<p>根据最近向证券交易委员会（SEC）披露的信息，Northern Trust Corp 在第四季度收购了 Tonix Pharmaceuticals Holding Corp.（NASDAQ:TNXP - 免费报告）的一项新股份。该公司收购了 489,735 股该公司的股票，价值约为 162,000 美元。在最近的报告期末，Northern Trust Corp 拥有 Tonix Pharmaceuticals 约 26.20% 的股份。</p>
<p>获取 <strong>Tonix Pharmaceuticals</strong> 警报：</p>
<ul>
<li>制药狂潮：波动性点燃生物技术行业</li>
</ul>
<p>另外，Commonwealth Equity Services LLC 在第四季度购买了价值 40,000 美元的 Tonix Pharmaceuticals 新股份。对冲基金和其他机构投资者拥有该公司 82.26% 的股票。</p>
<h2>华尔街分析师的看法</h2>
<p>几家研究公司最近对 TNXP 进行了评论。华尔街 Zen 在 5 月 30 日的研究报告中将 Tonix Pharmaceuticals 的评级从 “持有” 下调至 “卖出”。Noble Financial 在 3 月 20 日的报告中重申了 “跑赢大盘” 的评级，并对 Tonix Pharmaceuticals 的股票设定了 70.00 美元的目标价。</p>
<ul>
<li>Tonix Pharmaceuticals 是下一个生物技术突破吗？</li>
</ul>
<p><strong>获取我们关于 Tonix Pharmaceuticals 的最新股票报告</strong></p>
<h2>Tonix Pharmaceuticals 的内部交易</h2>
<p>在相关消息中，首席执行官 Seth Lederman 于 5 月 15 日以每股 21.55 美元的平均价格收购了 4,000 股该公司的股票，总价值为 86,200.00 美元。购买完成后，首席执行官现在直接拥有 4,005 股该公司的股票，价值为 86,307.75 美元。这代表着他们持有的股票增加了 80,000.00%。该购买在向证券交易委员会提交的文件中披露，文件可通过此超链接访问。公司内部人士拥有该公司 0.03% 的股票。</p>
<h2>Tonix Pharmaceuticals 股票上涨 6.3%</h2>
<p>TNXP 股票在周三开盘价为 40.45 美元。Tonix Pharmaceuticals Holding Corp. 的 52 周低点为 6.76 美元，52 周高点为 520.00 美元。该公司的 50 日移动平均线为 21.96 美元，200 日移动平均线为 22.55 美元。该公司的债务与股本比率为 0.07，速动比率为 2.81，流动比率为 3.33。该公司的市值为 2.963 亿美金，市盈率为-0.01，贝塔值为 1.63。</p>
<p>Tonix Pharmaceuticals（NASDAQ:TNXP - 获取免费报告）最近在 5 月 12 日发布了其财报。该公司报告本季度每股收益为（2.84 美元），超出分析师一致预期的（3.23 美元）0.39 美元。Tonix Pharmaceuticals 的股本回报率为-163.95%，净利润率为-1,197.86%。该公司本季度的收入为 243 万美元，而一致预期为 255 万美元。作为一个整体，分析师预测 Tonix Pharmaceuticals Holding Corp. 本年度每股收益将为-1762.5。</p>
<h2>关于 Tonix Pharmaceuticals</h2>
<p>（免费报告）</p>
<p>Tonix Pharmaceuticals Holding Corp. 是一家生物制药公司，专注于开发、发现、商业化和许可治疗人类疾病和减轻痛苦的疗法。它市场销售 Zembrace SymTouch 和 Tosymra，用于治疗成人急性偏头痛（有或没有先兆）。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Tonix Pharmaceuticals</li>
<li>股息支付比率计算器</li>
<li>市场上最被做空的：2 家空头头寸超过 40% 的公司</li>
<li>动荡市场中的资产配置策略</li>
<li>Ollie’s 第一季度财报：好、坏及未来展望</li>
<li>比较和交易高市盈率股票</li>
<li>Rocket Lab 扩展到有效载荷：你应该关注吗？</li>
</ul>
<p><strong>想看看其他对 TNXP 感兴趣的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Tonix Pharmaceuticals Holding Corp.（NASDAQ:TNXP - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5YUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5YUA"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Tonix Pharmaceuticals 吗？</h2>
<p>在考虑 Tonix Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Tonix Pharmaceuticals 并不在名单上。</p>
<p>虽然 Tonix Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

NTRS

Tonix 医药控股

<p>北方信托公司在第四季度收购了 489,735 股 Tonix Pharmaceuticals Holding Corp.（纳斯达克代码：TNXP），价值约为 162,000 美元，使其持股比例增加至 26.20%。英联邦证券服务公司也购买了价值 40,000 美元的股份。分析师对 TNXP 的看法不一，华尔街 Zen 将其评级下调至 “卖出”，而诺布尔金融则维持 “跑赢大盘” 的评级，目标价为 70 美元。最近，Tonix 的股票上涨了 6.3%，市值为 2.963 亿美元，报告的每股收益为-2.84，超出预期。该公司专注于开发人类疾病的治疗药物</p>

<p>Northern Trust Corp acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 489,735 shares of the company's stock, valued at approximately $162,000. Northern Trust Corp owned about 26.20% of Tonix Pharmaceuticals at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根据最近向证券交易委员会（SEC）披露的信息，Northern Trust Corp 在第四季度收购了 Tonix Pharmaceuticals Holding Corp.（NASDAQ:TNXP - 免费报告）的一项新股份。该公司收购了 489,735 股该公司的股票，价值约为 162,000 美元。在最近的报告期末，Northern Trust Corp 拥有 Tonix Pharmaceuticals 约 26.20% 的股份。</p>
</div><p>Get <strong>Tonix Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Tonix Pharmaceuticals</strong> 警报：</p>
</div><ul>
<li>Pharma Frenzy: Volatility Ignites Biotech Sector</li>
</ul>
<div class="lb-trans"><ul>
<li>制药狂潮：波动性点燃生物技术行业</li>
</ul>
</div><p>Separately, Commonwealth Equity Services LLC purchased a new stake in shares of Tonix Pharmaceuticals during the fourth quarter valued at $40,000. Hedge funds and other institutional investors own 82.26% of the company's stock.</p>
<div class="lb-trans"><p>另外，Commonwealth Equity Services LLC 在第四季度购买了价值 40,000 美元的 Tonix Pharmaceuticals 新股份。对冲基金和其他机构投资者拥有该公司 82.26% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>Several research firms recently commented on TNXP. Wall Street Zen cut Tonix Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Friday, May 30th. Noble Financial reissued an &#34;outperform&#34; rating and issued a $70.00 target price on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th.</p>
<div class="lb-trans"><p>几家研究公司最近对 TNXP 进行了评论。华尔街 Zen 在 5 月 30 日的研究报告中将 Tonix Pharmaceuticals 的评级从 “持有” 下调至 “卖出”。Noble Financial 在 3 月 20 日的报告中重申了 “跑赢大盘” 的评级，并对 Tonix Pharmaceuticals 的股票设定了 70.00 美元的目标价。</p>
</div><ul>
<li>Is Tonix Pharmaceuticals the Next Biotech Breakout?</li>
</ul>
<div class="lb-trans"><ul>
<li>Tonix Pharmaceuticals 是下一个生物技术突破吗？</li>
</ul>
</div><p><strong>Get Our Latest Stock Report on Tonix Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Tonix Pharmaceuticals 的最新股票报告</strong></p>
</div><h2>Insider Transactions at Tonix Pharmaceuticals</h2>
<div class="lb-trans"><h2>Tonix Pharmaceuticals 的内部交易</h2>
</div><p>In related news, CEO Seth Lederman acquired 4,000 shares of the firm's stock in a transaction dated Thursday, May 15th. The shares were purchased at an average price of $21.55 per share, with a total value of $86,200.00. Following the completion of the purchase, the chief executive officer now directly owns 4,005 shares of the company's stock, valued at $86,307.75. This represents a 80,000.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.03% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席执行官 Seth Lederman 于 5 月 15 日以每股 21.55 美元的平均价格收购了 4,000 股该公司的股票，总价值为 86,200.00 美元。购买完成后，首席执行官现在直接拥有 4,005 股该公司的股票，价值为 86,307.75 美元。这代表着他们持有的股票增加了 80,000.00%。该购买在向证券交易委员会提交的文件中披露，文件可通过此超链接访问。公司内部人士拥有该公司 0.03% 的股票。</p>
</div><h2>Tonix Pharmaceuticals Stock Up 6.3%</h2>
<div class="lb-trans"><h2>Tonix Pharmaceuticals 股票上涨 6.3%</h2>
</div><p>TNXP stock opened at $40.45 on Wednesday. Tonix Pharmaceuticals Holding Corp. has a fifty-two week low of $6.76 and a fifty-two week high of $520.00. The business's 50-day moving average is $21.96 and its two-hundred day moving average is $22.55. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company has a market cap of $296.30 million, a price-to-earnings ratio of -0.01 and a beta of 1.63.</p>
<div class="lb-trans"><p>TNXP 股票在周三开盘价为 40.45 美元。Tonix Pharmaceuticals Holding Corp. 的 52 周低点为 6.76 美元，52 周高点为 520.00 美元。该公司的 50 日移动平均线为 21.96 美元，200 日移动平均线为 22.55 美元。该公司的债务与股本比率为 0.07，速动比率为 2.81，流动比率为 3.33。该公司的市值为 2.963 亿美金，市盈率为-0.01，贝塔值为 1.63。</p>
</div><p>Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($2.84) earnings per share for the quarter, beating analysts' consensus estimates of ($3.23) by $0.39. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The company had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.55 million. As a group, analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current year.</p>
<div class="lb-trans"><p>Tonix Pharmaceuticals（NASDAQ:TNXP - 获取免费报告）最近在 5 月 12 日发布了其财报。该公司报告本季度每股收益为（2.84 美元），超出分析师一致预期的（3.23 美元）0.39 美元。Tonix Pharmaceuticals 的股本回报率为-163.95%，净利润率为-1,197.86%。该公司本季度的收入为 243 万美元，而一致预期为 255 万美元。作为一个整体，分析师预测 Tonix Pharmaceuticals Holding Corp. 本年度每股收益将为-1762.5。</p>
</div><h2>About Tonix Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Tonix Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.</p>
<div class="lb-trans"><p>Tonix Pharmaceuticals Holding Corp. 是一家生物制药公司，专注于开发、发现、商业化和许可治疗人类疾病和减轻痛苦的疗法。它市场销售 Zembrace SymTouch 和 Tosymra，用于治疗成人急性偏头痛（有或没有先兆）。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Tonix Pharmaceuticals</li>
<li>Dividend Payout Ratio Calculator</li>
<li>Among the Market’s Most Shorted: 2 Firms With +40% Short Interest</li>
<li>Asset Allocation Strategies in Volatile Markets</li>
<li>Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next</li>
<li>Comparing and Trading High PE Ratio Stocks</li>
<li>Rocket Lab Expands Into Payloads: Should You Be Paying Attention?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Tonix Pharmaceuticals</li>
<li>股息支付比率计算器</li>
<li>市场上最被做空的：2 家空头头寸超过 40% 的公司</li>
<li>动荡市场中的资产配置策略</li>
<li>Ollie’s 第一季度财报：好、坏及未来展望</li>
<li>比较和交易高市盈率股票</li>
<li>Rocket Lab 扩展到有效载荷：你应该关注吗？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TNXP?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 TNXP 感兴趣的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Tonix Pharmaceuticals Holding Corp.（NASDAQ:TNXP - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5YUA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TNXP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tonix Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Tonix Pharmaceuticals 吗？</h2>
</div><p>Before you consider Tonix Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Tonix Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Tonix Pharmaceuticals 并不在名单上。</p>
</div><p>While Tonix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Tonix Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Northern Trust Corp Acquires New Shares in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Northern Trust 公司收购了 Tonix 医药控股公司（NASDAQ:TNXP）的新股份